MRI can measure early benefits of cholesterol-lowering drugs
Using modified magnetic resonance imaging (MRI) techniques, researchers at Johns Hopkins have been able to detect the early benefits of a cholesterol-lowering medication much sooner than before. The researchers applied MRI to measure the success of simvastatin, a widely used form of so-called statin therapy, in reducing plaque formation in patients with hardened and clogged arteries, or atherosclerosis. Reductions in plaque levels were detected within six months after therapy began. Traditionally, MRI has been unable to show results until one or two years after the onset of treatment.